Posted by Michael Wonder on 28 Apr 2026
Breztri approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
28 April 2026 - Approval based on KALOS and LOGOS Phase 3 trials demonstrating statistically significant and clinically meaningful benefits of AstraZeneca’s single-inhaler fixed-dose triple therapy compared with inhaled dual therapy.
AstraZeneca’s fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) 320/36/9.6μg) has been approved in the US for the maintenance treatment of asthma in adult and paediatric patients 12 years of age and older.
